AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.07

+1.9%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$900.68M
EPS-1.7400
P/E Ratio-5.21
Earnings Date08/12/2026

spry

Short Term Investments

Last Annual Value

203.67M

3-Year CAGR

47%

5-Year CAGR

%

10-Year CAGR

%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Short Term Investments

SPRY · NASDAQ
CompanyShort Term Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
203.67M
9.0%N/AN/A 
73.46M
-9.7%9.8%-3.7%
SVRA logo
Savara Inc.
NASDAQ:SVRA
202.52M
14.3%9.8%N/A
518.14M
10.3%3.9%24.5%
0.00
N/AN/AN/A
267.17M
105.8%N/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
161.48M
-18.9%N/AN/A
178.62M
7.1%N/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
73.75M
-4.9%N/AN/A
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.07, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.07